View Older Stories View More Recent Stories

Jun 23, 2022 04:27PM Blueprint Medicines (BPMC) Appoints Habib Dable to its Board
Jun 23, 2022 04:26PM Blueprint Medicines Appoints Habib Dable to its Board of Directors
Jun 9, 2022 07:07AM Blueprint Medicines (BPMC) Reports Continued Progress Toward Goal of Transforming Treatment of Systemic Mastocytosis
Jun 9, 2022 07:00AM Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of Systemic Mastocytosis
Jun 3, 2022 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 5, 2022 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 3, 2022 07:00AM Blueprint Medicines Reports First Quarter 2022 Results
Apr 26, 2022 08:00AM Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
Apr 8, 2022 01:00PM Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung Cancer
Apr 6, 2022 04:00PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 25, 2022 10:15AM Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval for the Treatment of Adults with Advanced Systemic Mastocytosis
Mar 8, 2022 04:30PM Blueprint Medicines to Showcase Broad Precision Therapy Pipeline at AACR Annual Meeting 2022
Mar 4, 2022 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 28, 2022 08:01AM Blueprint Medicines (BPMC) and Proteovant Therapeutics Collaborate to Advance Novel Targeted Protein Degrader Therapies
Feb 28, 2022 08:00AM Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies
Feb 16, 2022 07:00AM Blueprint Medicines Reports Fourth Quarter and Full Year 2021 Results
Feb 11, 2022 04:00PM Blueprint Medicines to Present at Upcoming Investor Conferences
Feb 9, 2022 08:00AM Blueprint Medicines to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 16, 2022
Feb 4, 2022 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 28, 2022 08:01AM Blueprint Medicines (BPMC) Announces Positive CHMP Opinion for AYVAKYT
Jan 28, 2022 08:00AM Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis
Jan 20, 2022 08:00AM Blueprint Medicines Elevates Two Talented Leaders to its Executive Team
Jan 10, 2022 08:16AM Blueprint Medicines (BPMC) Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy Leadership
Jan 10, 2022 08:00AM Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy Leadership
Jan 6, 2022 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 5, 2022 08:04AM Blueprint Medicines (BPMC) Announces CEO and Leadership Transition Plan
Jan 5, 2022 08:00AM Blueprint Medicines Announces CEO and Leadership Transition Plan
Dec 30, 2021 08:51AM Blueprint Medicines Completes Acquisition of Lengo Therapeutics
Dec 9, 2021 04:01PM Blueprint Medicines (BPMC) Appoints Daniella Beckman to its Board
Dec 9, 2021 04:01PM Blueprint Medicines Appoints Daniella Beckman to its Board of Directors
Dec 7, 2021 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dec 6, 2021 04:02PM Blueprint Medicines (BPMC) Announces Publication of Results from Two Registration Studies of AYVAKIT Showing Sustained Benefits in Patients with Advanced Systemic Mastocytosis
Dec 6, 2021 04:01PM Nature Medicine Publishes Results from Two Registration Studies of AYVAKIT® (avapritinib) Showing Sustained Benefits in Patients with Advanced Systemic Mastocytosis
Nov 29, 2021 07:02AM Blueprint Medicines (BPMC) will acquire Lengo Therapeutics for up to $465 Million
Nov 29, 2021 07:00AM Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics
Nov 9, 2021 08:00AM Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China
Nov 9, 2021 08:00AM Blueprint Medicines and Zai Lab Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China
Nov 9, 2021 08:00AM Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China
Nov 5, 2021 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct 28, 2021 07:00AM Blueprint Medicines Reports Third Quarter 2021 Financial Results
Oct 21, 2021 08:00AM Blueprint Medicines to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021
Oct 5, 2021 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 3, 2021 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 2, 2021 08:00AM Blueprint Medicines to Present at Morgan Stanley 19th Annual Global Healthcare Conference
Aug 4, 2021 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jul 29, 2021 07:00AM Blueprint Medicines Reports Second Quarter 2021 Financial Results
Jul 28, 2021 08:00AM MD Anderson and Blueprint Medicines Announce Strategic Collaboration to Accelerate BLU-222 Development
Jul 22, 2021 08:00AM Blueprint Medicines to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021
Jul 7, 2021 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jun 16, 2021 03:52PM Blueprint Medicines (BPMC) Confirms FDA Approves AYVAKIT for the Treatment of Adults with Advanced Systemic Mastocytosis
View More Recent Stories View Older Stories